<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04116658</url>
  </required_header>
  <id_info>
    <org_study_id>EOGBM1-18</org_study_id>
    <nct_id>NCT04116658</nct_id>
  </id_info>
  <brief_title>First-in-Human, Phase 1b/2a Trial of a Multipeptide Therapeutic Vaccine in Patients With Progressive Glioblastoma</brief_title>
  <acronym>ROSALIE</acronym>
  <official_title>A Multicenter, Open-Label, First-in-Human, Phase 1b/2a Trial of EO2401, a Novel Multipeptide Therapeutic Vaccine, With and Without Check Point Inhibitor, Following Standard Treatment in Patients With Progressive Glioblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Enterome</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Covance</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Enterome</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability, immunogenicity, and&#xD;
      preliminary efficacy of EO2401 in patients with unequivocal evidence of progressive or first&#xD;
      recurrent glioblastoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, Phase 1b/2a, First-In-Human study to assess the safety, tolerability,&#xD;
      immunogenicity, and preliminary efficacy of EO2401 in patients with unequivocal evidence of&#xD;
      progressive or first recurrent glioblastoma.&#xD;
&#xD;
      EO2401 is an innovative cancer peptide therapeutic vaccine based on the homologies between&#xD;
      Tumor Associated Antigens and microbiome-derived peptides that will be administered alone and&#xD;
      in combination with nivolumab, and nivolumab/bevacizumab to generate preliminary safety and&#xD;
      efficacy data in patients with progressive glioblastoma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 13, 2020</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of EO2401: National Cancer Institute-Common Terminology Criteria for AEs (NCI-CTCAE) v5.0</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Incidences of AEs, treatment-emergent AEs (TEAEs), Serious Adverse Events ( SAEs), deaths, and laboratory abnormalities using the National Cancer Institute-Common Terminology Criteria for AEs (NCI-CTCAE) v5.0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of survival</measure>
    <time_frame>From end of treatment to at least 24 months after last patient enrollment</time_frame>
    <description>Overall survival, defined as the time interval from the date of first study treatment administration to the date of death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the immunogenicity of EO2316, EO2317, EO2318 (Three components of the therapeutic vaccine), and Universal Cancer Peptide that compose EO2401</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Immunogenicity will be assessed by Interferon-γ ELISpot</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Glioblastoma, Adult</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple dose of EO2041 monotherapy followed by continued EO2401 in combination with nivolumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple dose of EO2041 in combination with nivolumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple dose of EO2041 in combination with nivolumab and bevacizumab (US only)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Multiple dose of EO2401</intervention_name>
    <description>Multiple dose administration of EO2401 coadministered with or without nivolumab (and bevacizumab, US only) during the priming phase</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with unequivocal documented (including histological confirmation of&#xD;
             Glioblastoma-GB- at the primary diagnosis) evidence of first progression/recurrence of&#xD;
             GB on MRI, as defined by RANO criteria&#xD;
&#xD;
          2. Patients with :&#xD;
&#xD;
               -  for Cohorts 1, 2a, and 3: at least 1 measurable lesion&#xD;
&#xD;
               -  for Cohort 2b: no measurable enhancing disease&#xD;
&#xD;
          3. Patients with an age ≥ 18 years old&#xD;
&#xD;
          4. Patients who are human leukocyte antigen (HLA)-A2 positive&#xD;
&#xD;
          5. Patients with an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 or&#xD;
             Karnofsky performance status ≥ 70&#xD;
&#xD;
          6. Patients should have received standard primary therapy, including surgery (biopsy,&#xD;
             incomplete or complete resection), radiation, temozolomide, if applicable&#xD;
&#xD;
               1. Radiation therapy must have been finished 28 days before first study treatment&#xD;
                  administration&#xD;
&#xD;
               2. Patients who received temozolomide as adjuvant therapy must have stopped the&#xD;
                  treatment and have a wash-out period of 28 days before first study treatment&#xD;
                  administration (6 weeks for nitrosoureas and 5 half lives for experimental&#xD;
                  therapies)&#xD;
&#xD;
               3. Patients with unmethylated methylguanine-DNA-methyltransferase (MGMT) promoter&#xD;
                  can be included even if they have not received temozolomide prior to the&#xD;
                  inclusion in this clinical study)&#xD;
&#xD;
          7. Female patients of childbearing potential must have a negative serum pregnancy test&#xD;
             within 72 hours prior to dosing&#xD;
&#xD;
          8. Considering the embryofetal toxicity of the nivolumab shown on animals' models, the&#xD;
             following recommendations for contraception must be followed:&#xD;
&#xD;
             a. If not surgically sterile, female patients of childbearing potential age must use&#xD;
             highly effective contraception from signing the Informed Consent Form (ICF) through 6&#xD;
             months after the last treatment dose administered. Highly effective contraception&#xD;
             included: i. Combined (estrogen and progesterone containing) hormonal contraception&#xD;
             associated with inhibition of ovulation: Oral Intravaginal Transdermal ii.&#xD;
             Progestogen-only hormonal contraception associated with inhibition of ovulation: Oral&#xD;
             Injectable Implantable iii. Intrauterine device iv. Intrauterine hormone-releasing&#xD;
             system v. Bilateral tubal occlusion vi. Sexual abstinence. In each case of delayed&#xD;
             menstrual period (over 1 month between menstruations), confirmation of absence of&#xD;
             pregnancy is strongly recommended. This recommendation also applies to women of&#xD;
             childbearing potential with infrequent or irregular menstrual cycles.&#xD;
&#xD;
             b. If not surgically sterile, male with female partner of childbearing potential must&#xD;
             use condom from signing the ICF through 8 months after the last treatment dose&#xD;
             administered. Males must ensure that their partners of childbearing potential use&#xD;
             highly effective contraception also.&#xD;
&#xD;
          9. Patients having received the information sheet and who have provided written informed&#xD;
             consent prior to any study-related procedures&#xD;
&#xD;
         10. Patients willing and able to comply with the scheduled visits, treatment plan,&#xD;
             laboratory tests, and other study procedures indicated in the protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients treated with dexamethasone &gt; 2 mg/day or equivalent (i.e., 13 mg/day of&#xD;
             prednisone) within 14 days before the first EO2401 administration, unless required to&#xD;
             treat an adverse event (AE) Note: The criterion implios the patient should not receive&#xD;
             treatment with dexamethasone &gt; 2 mg/day or equivalent at the actual time of a&#xD;
             screening visit (single time point assessment), and within 14 days before the first&#xD;
             EO2401 administration (unless required to treat AE); the latter part of the criterion&#xD;
             should be checked at the time of treatment start.&#xD;
&#xD;
          2. 2. Patients treated with radiotherapy, and cytoreductive therapy within 28 days (6&#xD;
             weeks for nitrosoureas) before the first EO2401 administration. In addition, patients&#xD;
             should not have received any prior treatment with compounds targeting PD-1, PD-L1,&#xD;
             CTLA-4, or similar compounds where general resistance against therapeutic vaccination&#xD;
             approaches might have developed; also, patients should not have received systemic&#xD;
             anti-tumor treatment or radiotherapy for their progressive or first recurrent GB.&#xD;
&#xD;
          3. Patients with tumors primarily located in the infra-tentorial segment&#xD;
&#xD;
          4. Patients with known radiological evidence of extracranial metastases&#xD;
&#xD;
          5. Patients with presence of new hemorrhage (excluding, stable Grade 1) or uncontrolled&#xD;
             seizure&#xD;
&#xD;
          6. Patients with significant leptomeningeal disease&#xD;
&#xD;
          7. Patients with abnormal (≥ Grade 2 National Cancer Institute-Common Terminology&#xD;
             Criteria for AEs [NCI-CTCAE] version 5.0) laboratory values for hematology, liver, and&#xD;
             renal function (serum creatinine). In detail, the following values apply as exclusion&#xD;
             criteria:&#xD;
&#xD;
               1. Hemoglobin &lt; 10 g/dL (6.2 mmol/L)&#xD;
&#xD;
               2. White blood cell count decrease (&lt; 3.0 × 109/L) or increase (&gt; 10.0 × 109/L)&#xD;
&#xD;
               3. Absolute neutrophil count decrease (&lt; 1.5 × 109/L)&#xD;
&#xD;
               4. Platelet count decrease (&lt; 75 × 109/L)&#xD;
&#xD;
               5. Bilirubin &gt; 1.5 × upper limit of normal (ULN; according to the performing&#xD;
                  laboratory's reference ranges)); Note, benign hereditary hyperbilirubinemia, e.g.&#xD;
                  Gilbert's syndrome is permitted.&#xD;
&#xD;
               6. Alanine aminotransferase &gt; 3 × ULN&#xD;
&#xD;
               7. Aspartate aminotransferase &gt; 3 × ULN&#xD;
&#xD;
               8. Gamma-glutamyltransferase &gt; 2.5 × ULN&#xD;
&#xD;
               9. Serum creatinine increase (&gt; 1.5 × ULN)&#xD;
&#xD;
              10. Abnormal thyroid function: 0.3 &gt; thyroid-stimulating hormone &gt; 5 μU(μunit)/mL and&#xD;
                  8.6 &gt; free T4 &gt; 25 pmol/L.&#xD;
&#xD;
          8. For patients who are planned to receive bevacizumab:&#xD;
&#xD;
               1. Patients with nephrotic syndrome&#xD;
&#xD;
               2. Patients with proteinuria ≥ 2g/24 hours&#xD;
&#xD;
               3. Patients with history or active gastrointestinal perforation and fistula&#xD;
&#xD;
               4. Significant surgical procedure in the 4 weeks preceding the start of treatment or&#xD;
                  planned surgery&#xD;
&#xD;
               5. Unhealed wound&#xD;
&#xD;
               6. Patient with recent (4 weeks) history of hemoptysis of ½ teaspoon or more of red&#xD;
                  blood&#xD;
&#xD;
               7. Thrombotic episode within 6 months&#xD;
&#xD;
               8. Uncontrolled diabetes mellitus or hypertension&#xD;
&#xD;
               9. Posterior reversible encephalopathy syndrome&#xD;
&#xD;
          9. Patients with persistent Grade 3 or 4 toxicities (according to NCI-CTCAE v5.0).&#xD;
             Toxicities must be resolved since at least 2 weeks to Grade 1 or less. However,&#xD;
             alopecia or other persisting toxicities Grade ≤ 2 not constituting a safety risk based&#xD;
             on Investigator's judgment is acceptable&#xD;
&#xD;
         10. Patients with contraindication to contrast-enhanced MRI&#xD;
&#xD;
         11. Other malignancy or prior malignancy with a disease-free interval of less than 3 years&#xD;
             except those treated with surgical intervention and an expected low likelihood of&#xD;
             recurrence such as basal cell or squamous cell skin cancer, or carcinoma in situ.&#xD;
             Patients with adequately treated basal cell or squamous cell skin cancer, or carcinoma&#xD;
             in situ are eligible&#xD;
&#xD;
         12. 12. Patients with clinically significant active infection, cardiac disease,&#xD;
             significant medical or psychiatric disease/condition that, in the opinion of the&#xD;
             Investigator, would interfere with the evaluation of EO2401 or interpretation of&#xD;
             patient safety or study results or that would prohibit the understanding or rendering&#xD;
             of informed consent (i.e. only consent able patients can be enrolled in the study) and&#xD;
             compliance with the requirements of the protocol - including (but not limited to):&#xD;
&#xD;
               1. Bacterial sepsis or other similarly severe infections&#xD;
&#xD;
               2. New York Heart Association &gt; Grade 2 congestive heart failure within 6 months&#xD;
                  prior to study entry&#xD;
&#xD;
               3. Uncontrolled or significant cardiovascular disease, including:&#xD;
&#xD;
             i. Myocardial infarction within 6 months prior to obtaining informed consent ii.&#xD;
             Uncontrolled/unstable angina within 6 months prior to obtaining informed consent iii.&#xD;
             Diagnosed or suspected congenital long QT syndrome iv. Any history of clinically&#xD;
             significant ventricular arrhythmias (such as ventricular tachycardia, ventricular&#xD;
             fibrillation, or Torsades de pointes) d. Stroke within 6 months prior obtaining&#xD;
             informed consent e. Concurrent neurodegenerative disease f. Dementia or significantly&#xD;
             altered mental status.&#xD;
&#xD;
         13. Patients with suspected autoimmune or active autoimmune disorder or known history of&#xD;
             an autoimmune neurologic condition (e.g., Guillain-Barré syndrome) Note, patients with&#xD;
             vitiligo, type I diabetes mellitus, hypothyroidism due to autoimmune condition only&#xD;
             requiring hormone replacement therapy, psoriasis not requiring systemic therapy, or&#xD;
             conditions not expected to recur in the absence of an external trigger are permitted&#xD;
             to enroll&#xD;
&#xD;
         14. Patients with history of solid organ transplantation or hematopoietic stem cell&#xD;
             transplantation&#xD;
&#xD;
         15. Patients with history or known presence of tuberculosis&#xD;
&#xD;
         16. Pregnant and breastfeeding patients&#xD;
&#xD;
         17. Patients with history or presence of human immunodeficiency virus and/or potentially&#xD;
             active hepatitis B virus/hepatitis C virus&#xD;
&#xD;
         18. Patients who have received live or attenuated vaccine therapy used for prevention of&#xD;
             infectious diseases including seasonal (influenza) vaccinations within 4 weeks of the&#xD;
             first dose of study drug&#xD;
&#xD;
         19. Patients with a history of hypersensitivity to any excipient present in the&#xD;
             pharmaceutical form of investigational medicinal product&#xD;
&#xD;
         20. Patients under treatment with immunostimulatory or immunosuppressive medications,&#xD;
             including herbal remedies, or herbal remedies known to potentially interfere with&#xD;
             major organ function&#xD;
&#xD;
         21. Patients with known drug and alcohol abuse&#xD;
&#xD;
         22. Patients with known or underlying medical or psychiatric condition that, in the&#xD;
             Investigator's opinion, would make the administration of study drug hazardous to the&#xD;
             patient or obscure the interpretation of toxicity determination or AEs&#xD;
&#xD;
         23. Patients who have received treatment with any other investigational agent, or&#xD;
             participation in another clinical trial (clinical trial including active interventions&#xD;
             are prohibited; participation in clinical trials for data collection purposes only are&#xD;
             permitted) within 28 days prior to first study treatment administration and during the&#xD;
             treatment period. Note, for investigational agents there should be a wash-out period&#xD;
             of at least 28 days, or 5 half-lives if longer, before first study treatment&#xD;
             administration&#xD;
&#xD;
         24. Patients deprived of their liberty or under protective custody or guardianship.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Reardon</last_name>
      <phone>617-632-2166</phone>
      <email>David_Reardon@DFCI.HARVARD.EDU</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François Ghiringhelli</last_name>
      <phone>+33 3 45 34 80 68</phone>
      <email>FGhiringhelli@cgfl.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Pitié-Salpétrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed Idbaih</last_name>
      <phone>+33 1 42 16 41 61</phone>
      <email>ahmed.idbaih@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik für Neurologie Universitätsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt Goethe-Universität Dr. Senckenbergisches Institut für Neuroonkologie</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60528</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Burger</last_name>
      <phone>+49 (0) 69630187711</phone>
      <email>michael.burger@kgu.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Neurologische Klinik &amp; Nationales Zentrum für Tumorenerkrankungen Heidelberg Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolfgang Wick</last_name>
      <phone>+ 49 6221 56 7075</phone>
      <email>Wolfgang.Wick@med.uni-heidelberg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Fakultät Mannheim der Universität Heidelberg</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iris Mildenberger</last_name>
      <phone>+49 621 383 2885</phone>
      <email>iris.mildenberger@umm.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zentrum für Neuroonkologie Universitätsklinikum Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ghazaleh Tabatabai</last_name>
      <phone>+49 7071 29 83269</phone>
      <email>ghazaleh.tabatabai@med.uni-tuebingen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Vieito</last_name>
      <phone>+34 664562847</phone>
      <email>mvieito@vhio.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institit Catala D'Oncologia - Hospital Duran i Reynals</name>
      <address>
        <city>Hospitalet De Llobregat</city>
        <zip>8908</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agostina Stradella</last_name>
      <phone>+34 932607744</phone>
      <email>astradella@iconcologia.net</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>September 30, 2019</study_first_submitted>
  <study_first_submitted_qc>October 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2019</study_first_posted>
  <last_update_submitted>July 16, 2021</last_update_submitted>
  <last_update_submitted_qc>July 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glioblastoma</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Nivolumab</keyword>
  <keyword>Bevacizumab</keyword>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

